

AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-18. (Canceled).

19. (Currently amended): A cell targeting conjugate comprising the following components that are covalently conjugated via a hydrazone, disulphide or amide bond linker that is degradable within the target cells:

a DNA minor groove binding ligand incorporating an effective Auger electron-emitting, and/or gamma-emitting and/or positron-emitting atom or photoactive moiety;
a target cell specific protein or peptide that is capable of internalisation by target cells;
~~wherein the linker comprises a hydrazone, and/or disulphide and/or amide bond, cell targeting conjugate is represented by Formula (I), wherein:~~



Formula (I)

X is carbon or nitrogen;

Y₁ and Y₂ are selected from C(R'), nitrogen, N(R'), oxygen and sulfur, wherein R' is hydrogen, optionally substituted alkyl or optionally substituted alkenyl, and wherein Y₁ and Y₂ are not both either C(R') or nitrogen;

---- is a double bond unless the attached Y₁ or Y₂ is N(R'), oxygen or sulfur in which case it is a single bond;

R₁ to R₁₂ are selected from hydrogen, halogen, hydroxy, amino, optionally substituted alkyl, optionally substituted alkenyl, a moiety including a target cell specific protein or peptide, an Auger electron-emitting moiety, a gamma-emitting moiety, a positron-emitting moiety and a photoactive moiety, and wherein two of R₁ to R₅ may together form optionally substituted cycloalkyl, cycloalkenyl or aryl; wherein one of R₁ to R₁₂ comprises a target cell specific protein or peptide, and wherein one other of R₁ to R₁₂ comprises an Auger electron-emitting moiety, a gamma-emitting moiety, a positron-emitting moiety or a photoactive moiety;
and salts and/or tautomers thereof.

20. (Canceled).

21. (Currently amended): The cell targeting conjugate according to claim 19 wherein the target cell specific protein or peptide is selected from anti-A33, C595, 4D5, trastuzumab (*Herceptin*), egf/R3, humanized h-R3, C225 (*Erbritux*), BrE-3, murine A7, C50, humanized MN-14, anti-A33, MSN-1, bivatuzumab, U36, KIS1, HuM195, anti-CD45, anti-CD19, TXU(anti-CD7)-pokeweed antiviral protein, M195, anti-CD23, apolizumab (Hu1D10), Campath-1H, N901, Ep2, somatostatin analogues, tositumomab (*Bexxar*), ibritumomab tiuxetan (*Zevalin*), HB22.7, anti-CD40, OC125, PAM4 and J591.


22-31. (Canceled).


32. (Currently amended) The ~~method~~ cell targeting conjugate according to claim 25
19 wherein the gamma-emitting and/or positron-emitting ~~atom~~ moiety is distanced from a DNA
minor groove binding region of the conjugate.

33. (Canceled).

34. (Canceled).

35. (New): A cell targeting conjugate according to claim 32 selected from the
following:





,
wherein R represents hydrogen, hydroxy, amino, halogen or optionally substituted alkyl,
alkenyl or alkynyl, and wherein I represents the gamma-emitting or positron-emitting moiety.